Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase III Trial Of NovoEight
June 25, 2015 at 11:17 AM EDT
Danish healthcare giant Novo Nordisk A/S (ADR) (NYSE: NVO) has developed NovoEight for the treatment and prevention of bleeding in ...
